CLINICAL BREAST CANCER, vol.21, no.1, pp.80-98, 2021 (SCI-Expanded)
Article / Article
CLINICAL BREAST CANCER
Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Adjuvant therapy, Disease-free survival, Distant disease-free survival, Neoadjuvant therapy, Overall survival, PLUS ADJUVANT CHEMOTHERAPY, DOUBLE-BLIND, TRASTUZUMAB, THERAPY, MULTICENTER, SURVIVAL, OUTCOMES
Dokuz Eylül University Affiliated:
In the patient population with early-stage human epidermal growth factor receptor 2-positive/hormone receptor-positive breast cancer who initiate neratinib within 1 year of trastuzumab-based therapy, the absolute 5-year invasive disease-free survival benefit versus placebo is 5.1%, and absolute 8-year overall survival benefit is 2.1%. Among those with residual disease after neoadjuvant therapy (non-pathologic complete response), absolute gains with neratinib are 7.4% and 9.1%, respectively.